Key Highlights
- Zura Bio (NASDAQ:ZURA) fell about 76% to near USD 0.97 on November 9, 2026, after touching an intraday record low of USD 0.93, on track for its worst single-day decline.
- The Phase 2 TibuSHIELD trial of tibulizumab in 247 patients with moderate-to-severe hidradenitis suppurativa missed its primary endpoint and key secondary endpoints at both doses tested.
- The company has discontinued development of tibulizumab in hidradenitis suppurativa and will focus on systemic sclerosis and polymyalgia rheumatica.
- Cash and equivalents were USD 187.7 million at September 30, 2026, which the company says funds operations through at least the end of 2028.
What the Trial Showed
The failure for Zura Bio (NASDAQ:ZURA) came from a small gap between drug and placebo. The primary endpoint was the relative change in abscess and inflammatory nodule count at Week 16. Patients on the 300 mg dose saw a 56.0% reduction and those on 150 mg a 58.1% reduction, but the placebo group improved by 52.5%, leaving no meaningful difference. Response rates on the HiSCR50 measure were 48.0% and 52.7% on drug against 45.5% on placebo, and on the stricter HiSCR75 measure 35.3% and 34.0% against 28.1%. High placebo responses are a known problem in hidradenitis suppurativa trials, but the results gave no clear signal that the drug works in this disease. Treatment-emergent adverse events occurred in 52.4% of patients in each drug group against 46.3% on placebo. One death from cardiac arrest in the 300 mg group was judged unrelated to treatment by the site investigator. An inflammatory bowel disease flare was also reported in the 300 mg group, a known consideration for drugs that act on the IL-17 pathway.
Why the Stock Collapsed
Hidradenitis suppurativa was the most visible and commercially attractive indication for tibulizumab, a dual inhibitor of the IL-17 and BAFF pathways, and investors had treated it as the company's main near-term value driver. Removing it leaves Zura Bio with programs whose results are further away: the Phase 2 TibuSURE study in systemic sclerosis is due to report topline data in the first half of 2027, and the NEXUS-PMR study in polymyalgia rheumatica is set to start by the end of 2026, with results expected in the fourth quarter of 2028. The company also holds torudokimab and crebankitug, both of which have completed early-stage studies. With the share price now below USD 1.00, the market is valuing the company close to its cash, which signals little confidence in the remaining pipeline. Chief executive Sandeep Kulkarni said the company will continue to study dual IL-17 and BAFF inhibition in systemic sclerosis and polymyalgia rheumatica, where the biology may be a better fit.
Risks and What to Watch
A share price under USD 1.00 raises the possibility of a Nasdaq minimum bid notice if it persists for 30 consecutive trading days, and the company may eventually consider a reverse split to regain compliance. Zura Bio (NASDAQ:ZURA) also faces Shareholder investigation notices, which are common after large one-day falls. The key question is whether the remaining programs justify continued spending or whether the board pursues strategic alternatives. Investors should watch additional pharmacokinetic and exposure analyses from TibuSHIELD, which could explain the result, the timing of the systemic sclerosis readout in early 2027 and any change in spending plans that would affect the cash runway into 2028. For holders, the remaining value now rests largely on cash and on a few years of clinical work whose outcome is uncertain.
Where Things Stand
Zura Bio lost about 76% on November 9, 2026 after its lead drug failed to separate from placebo in a 247-patient hidradenitis suppurativa trial, and the company dropped the indication. It still has USD 187.7 million in cash and programs in systemic sclerosis and polymyalgia rheumatica. The systemic sclerosis readout in the first half of 2027 is now the main catalyst.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...